NCT00486356View on ClinicalTrials.gov

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 1, 2004

Primary Completion Date

January 1, 2010

Study Completion Date

January 1, 2010

Conditions
Extrahepatic Bile Duct CancerGallbladder CancerGastric CancerLiver CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

capecitabine

DRUG

carboplatin

DRUG

epirubicin hydrochloride

GENETIC

microarray analysis

GENETIC

polymorphism analysis

OTHER

pharmacological study

Trial Locations (1)

68198-6805

University of Nebraska Medical Center, Eppley Cancer Center, Omaha

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Nebraska

OTHER

NCT00486356 - Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer | Biotech Hunter | Biotech Hunter